We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
3.00 | 0.18% | 1,673.00 | 1,674.00 | 1,675.00 | 1,679.50 | 1,658.50 | 1,661.50 | 7,034,492 | 16:35:02 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 13.99 | 68.96B |
Date | Subject | Author | Discuss |
---|---|---|---|
14/2/2017 07:24 | It is fantastic news, although not unexpected. Have mentioned the two drug regime potential a number of times, what it will hopefully do is take further share in this market. There will be a cost saving benefit and a side effect profile benefit for patients With growing pressures on healthcare budgets it is a very welcome development. | essentialinvestor | |
14/2/2017 07:21 | Yep, all good here, sitting on the throne reading the rns. John C Pottage, Jr, MD, Chief Scientific and Medical Officer, ViiV Healthcare, commented, "The results from these studies may change our understanding of how HIV can be managed. For more than 20 years we thought that three or more drugs were required to maintain virologic suppression, but the SWORD studies provide compelling data that suppression may be maintained with a two drug regimen of dolutegravir and rilpivirine. These data mark an exciting first step towards making two drug regimens a reality in HIV treatment. We are planning regulatory submissions for this two-drug regimen as a single tablet in 2017." | ny boy | |
14/2/2017 07:18 | Anybody alive???ViiV results in. | phatprofit | |
13/2/2017 09:02 | 13th feb Jefferies buy tp 1780p 10th feb JP Morgan neutral tp 1670p up from 1600p | philanderer | |
11/2/2017 09:46 | Great. Thanks for posts. | philo124 | |
11/2/2017 07:43 | GSK ex div (again) in under 2 weeks ...... ;0) | tradermichael | |
10/2/2017 15:51 | The pull back was a bear trap, soon we can break 1615p and head for 1700p | ny boy | |
10/2/2017 11:02 | Yep, that`s what it was... " UK Industrial Production Growth Tops Expectations " | philanderer | |
10/2/2017 10:45 | Hmm could be pound related then. | tim 3 | |
10/2/2017 09:55 | Did they cut BATS too as the share price trace was pretty much identical to GSK | andyadvfn1 | |
10/2/2017 09:48 | See above cut came out at 9.10. | tim 3 | |
10/2/2017 09:47 | andy, I think Trump said something in his sleep about pharma's being the next on the list after he has finished with the appeals court judges. | solomon | |
10/2/2017 09:45 | After a nice rise this morning why the sudden reversal...pound related ? | andyadvfn1 | |
10/2/2017 09:35 | Deutsche Bank today reaffirms its hold investment rating on GlaxoSmithKline PLC (LON:GSK) and cut its price target to 1720p (from 1800p). Story provided by StockMarketWire.com | tim 3 | |
10/2/2017 08:37 | Usually get that when approaching a market top, buyer exhaustion philanderer. GSK will be a defensive play when markets turn south. Happy holding and collecting a nice divi, I think 6%+! | ny boy | |
09/2/2017 10:22 | The bond proxy stocks had a nice few days with yields suggesting inflationary expectations are muted, big move on the UK 10-Year over the last week. May also explain why real estate is getting some support. | essentialinvestor | |
09/2/2017 10:17 | Market seems stuck this morning . Just GSK , AZN and MKS moving for me , everything else dead as a dodo | philanderer | |
09/2/2017 09:43 | FWIW reiterations today... 9th feb Deutsche hold tp 1800p 9th feb JP Morgan neutral tp 1600p 9th feb Liberum buy tp 1900p | philanderer | |
09/2/2017 09:08 | Broker upgrade to 1900p. Solid play 5% divi at present ..I've been buying more this morning for the pension fund. | ny boy | |
09/2/2017 08:52 | Very welcome. | essentialinvestor | |
09/2/2017 08:41 | Onwards to 1700p | ny boy | |
08/2/2017 20:34 | GSK needs no medicine despite talk of poor performance | philanderer | |
08/2/2017 17:19 | Very nice recovery, thought we may have got a double dip, the considered reaction was more positive. | essentialinvestor | |
08/2/2017 16:41 | Nice dip buying at support, onwards & upwards | ny boy |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions